指南与共识产科母胎医学

母胎医学会咨询系列#56:妊娠期丙型肝炎更新指南

Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017.
指南 / 共识 · Am J Obstet Gynecol · 2021-06-08

该指南由母胎医学会制定,讨论妊娠期丙型肝炎病毒的筛查、治疗和管理。推荐所有孕妇每次妊娠筛查抗-HCV抗体(GRADE 1B),反对仅因HCV行剖宫产(GRADE 1B),并建议避免内部胎儿监护和早期人工破膜(GRADE 2B)。

要点

  • 所有孕妇每次妊娠均应筛查抗-HCV抗体(GRADE 1B)。
  • 反对仅因HCV感染行剖宫产(GRADE 1B)。
  • 避免内部胎儿监护和早期人工破膜,除非必要(GRADE 2B)。

核心结论

  • 推荐所有孕妇每次妊娠筛查抗-HCV抗体(GRADE 1B)。
  • 反对仅因HCV感染行剖宫产(GRADE 1B)。
  • 建议避免内部胎儿监护和早期人工破膜,除非必要(GRADE 2B)。
  • HCV状态不应改变标准母乳喂养咨询,除非乳头皲裂或出血(GRADE 1A)。

研究设计与样本

  • 母胎医学会制定的咨询系列指南,更新2017年咨询#43。

主要发现

  • 美国估计1%至4%孕妇感染HCV,母婴传播风险约5%。
  • HCV感染与胎儿生长受限和低出生体重等不良胎儿结局风险增加相关。

关键数值与推荐

  • 建议孕晚期评估胎儿生长,但仅HCV诊断不指示产前检测(GRADE 2C)。
  • 建议对早发型或高胆汁酸水平的肝内胆汁淤积症孕妇筛查病毒性肝炎(GRADE 2C)。
  • 建议HCV阳性孕妇筛查其他性传播感染,包括HIV、梅毒、淋病、衣原体和HBV(GRADE 2C)。
  • 推荐HCV患者接种甲肝和乙肝疫苗(如未免疫)(GRADE 1B)。
  • 推荐直接抗病毒方案仅在临床试验中于孕期启动(GRADE 1C)。

临床怎么用

  • 对所有孕妇每次妊娠进行抗-HCV抗体筛查。
  • HCV阳性孕妇应筛查其他性传播感染并接种甲肝和乙肝疫苗。
  • 避免仅因HCV行剖宫产,避免不必要的内部胎儿监护和早期人工破膜。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the United States, it is estimated that 1% to 4% of pregnant women are infected with hepatitis C virus, which carries approximately a 5% risk of transmission from mother to infant. Hepatitis C virus can be transmitted to the infant in utero or during the peripartum period, and infection during pregnancy is associated with an increased risk of adverse fetal outcomes, including fetal growth restriction and low birthweight. The purpose of this document is to discuss the current evidence, provide updated recommendations regarding screening, review treatment, and address management of hepatitis C virus during pregnancy. The following are the Society for Maternal-Fetal Medicine's recommendations: (1) We suggest that third trimester assessment of fetal growth may be performed, but antenatal testing is not indicated in the setting of hepatitis C virus diagnosis alone (GRADE 2C); (2) we suggest screening for viral hepatitis in patients with a diagnosis of intrahepatic cholestasis of pregnancy at an early gestational age or with high levels of bile acids (GRADE 2C); (3) we recommend that obstetrical providers screen all pregnant patients for hepatitis C virus by testing for anti-hepatitis C virus antibodies in every pregnancy (GRADE 1B); (4) we suggest that obstetrical care providers screen hepatitis C virus-positive pregnant patients for other sexually transmitted infections (if not done previously), including human immunodeficiency virus, syphilis, gonorrhea, chlamydia, and hepatitis B virus (GRADE 2C); (5) we recommend vaccination against hepatitis A and B viruses (if not immune) for patients with hepatitis C virus (GRADE 1B); (6) we recommend that direct-acting antiviral regimens only be initiated in the setting of a clinical trial during pregnancy and that people who become pregnant while taking a direct-acting antiviral should be counseled in a shared decision-making framework about the risks and benefits of continuation (GRADE 1C); (7) we suggest that if prenatal diagnostic testing is requested, patients are counseled that data regarding the risk of vertical transmission are reassuring but limited (GRADE 2C); (8) we recommend against cesarean delivery solely for the indication of hepatitis C virus (GRADE 1B); (9) we suggest that obstetrical care providers avoid internal fetal monitors and early artificial rupture of membranes when managing labor in patients with hepatitis C virus unless necessary in the course of management (ie, when unable to trace the fetal heart rate with external monitors and the alternative is proceeding with cesarean delivery) (GRADE 2B); (10) we recommend that hepatitis C virus status not alter standard breastfeeding counseling and recommendations unless nipples are cracked or bleeding (GRADE 1A).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dotters-Katz SK, Kuller JA, Hughes BL, et al. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. Am J Obstet Gynecol. 2021. PMID: 34116035. doi:10.1016/j.ajog.2021.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。